title: [New treatments of hereditary blindness].
abstract: Ongoing clinical trials are targeting several previously intractable hereditary causes of blindness of congenital, childhood or early adulthood onset, mainly in the optic nerve and retina. The intended stage of initiation of the new therapeutic approaches ranges from neonatal life and a structurally intact retinal tissue to adult life with a complete loss of photoreceptors. It must be assumed that some of the trials will succeed in producing new therapies and action must be taken to refine and accelerate diagnostics and to preserve therapeutic potential in blind people.
authors.affiliation: Øjenklinikken, Kennedy Centret, Gammel Landevej 7, Glostrup. mette.bertelsen@regionh.dk
authors.forename: Mette
authors.initials: M
authors.lastname: Bertelsen
authors.forename: Thomas
authors.initials: T
authors.lastname: Rosenberg
authors.forename: Michael
authors.initials: M
authors.lastname: Larsen
mesh_terms: D001766:Blindness / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics / Q000628:therapy*; D003718:Denmark / Q000453:epidemiology; D004567:Electrodes, Implanted; D015785:Eye Diseases, Hereditary / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics / Q000628:therapy*; D015316:Genetic Therapy; D006801:Humans; D012174:Retinitis Pigmentosa / Q000453:epidemiology / Q000235:genetics / Q000473:pathology / Q000628:therapy; D012176:Retinoids / Q000008:administration & dosage / Q000627:therapeutic use; D057488:Visual Prosthesis
chemical_list: D012176:Retinoids